AMedP-8.17
AMedP-8.17 minimum standards for oxygen 93 percent produced on operations
Participating NATO nations' pharmacists and medical technicians who produce oxygen on operations, and the manufacturers of the generating systems and containers a contract specifies
AMedP-8.17 sets NATO's minimum requirements for Oxygen 93 Percent, the medicinal gas produced in the field by mobile and portable oxygen generating systems, covering its quality, testing and the interoperability that lets nations exchange it during operations.
- Edition
- A
- Published
- 2021-12
What it is
What AMedP-8.17 standardises
AMedP-8.17 is a NATO Allied Medical Publication that sets the minimum requirements for Oxygen 93 Percent, a medicinal gas produced in the field, on operations, rather than resupplied forward in pressurized containers. The document states it "primarily addresses pharmacists and medical technicians," and it is intended to apply to any member nation, service or organisation that uses Oxygen 93 Percent, as well as to military testing or research institutions working with medicinal oxygen equipment.
Its purpose is as much interoperability as quality. Participating nations agree that installations producing Oxygen 93 Percent, and the oxygen itself, meet the document's minimum requirements, that they follow its procedures, and that they notify other nations participating in mutual medical support when they cannot meet them. The aim is to "enhance the effectiveness of NATO forces when conducting joint operations" by introducing a uniform, safe level of oxygen production, so participating nations can share production and container-filling capacity, and exchange filled containers, when hosting or supporting another nation's medical teams.
How the oxygen is produced
Oxygen 93 Percent is produced from ambient or compressed air by the molecular sieve process, and the document sets requirements for the two classes of equipment that produce it: Mobile Oxygen Generating Systems (MOGS) and Portable Oxygen Generating Systems (POGS). Both are required to carry continuous monitoring so that oxygen purity and contaminant levels stay within acceptable limits, and both must produce oxygen that meets the applicable pharmacopoeia monograph. This page does not reproduce the operating ranges, redundancy arrangements or purity figures the document sets for either system.
Pressurized containers filled from a MOGS or POGS carry their own requirements: a colour code and label, a serial number and a batch number as the minimum traceability standard, and a quality certificate accompanying the product, with the specific form of that certificate "left to national discretion in accordance with national legislations and the respective pharmacopoeia."
Quality, testing, and the pharmacopoeia link
AMedP-8.17 does not set its own, separate chemistry for what counts as acceptable Oxygen 93 Percent. The document requires that "the quality of the oxygen produced must meet the regulations of the United States Pharmacopoeia – National Formulary (USP-NF) or the European Pharmacopoeia (Ph. Eur.) monographs, depending on the national legislation of the manufacturing member nation," and an annex compares the two pharmacopoeias' Oxygen 93 Percent monographs side by side. Analysis is referenced to standard reference conditions the document specifies, using methods the national pharmacopoeias describe, and a sampling regime covers production, filled containers, and testing after any maintenance or repair, with the records kept available for a period the document sets. Test authorities and procedures are required to have "reached an approved standard," and all equipment must carry traceable calibration. This page does not reproduce the purity or contaminant limits themselves.
How it binds, and where nations diverge from it
Nations' agreement to use AMedP-8.17 is recorded in STANAG 2558; as with any STANAG-covered publication, that is a national commitment carrying whatever reservations a nation has recorded, not something that applies uniformly by default. Four are recorded against this edition: the Czech Republic against specific points of the publication, Greece because its armed forces hold neither a MOGS nor a POGS, the Netherlands over how its monitoring is documented rather than transmitted electronically, and Turkey pending its own procurement and procedures. Edition A, Version 2 was promulgated in December 2021, took effect on receipt, and superseded Edition A, Version 1, which the promulgation letter directs be destroyed under local procedure.
What it does not cover
The document names no certification, accreditation or inspection scheme, and no organisation is assessed against AMedP-8.17 the way a management system is audited against ISO 9001. Conformity shows up as a quality certificate travelling with each batch, and records of the sampling, analysis and calibration Chapter 4 describes, held against whichever pharmacopoeia the manufacturing nation's own legislation applies - not against AMedP-8.17 as a standalone certificate.
Getting the document
NATO publishes AMedP-8.17 free of charge through the NATO Standardization Document Database. ComplyTrain does not sell it or hold a copy for distribution; the NSDD listing for AMedP-8.17 is the source.
How we help
AMedP-8.17 is an operational and technical standard, not a management system: the substantive work
- producing oxygen to the required purity, running the sampling and analysis regime, calibrating
the equipment, filling and labelling containers - happens on the equipment and in the field, not in software. A unit producing or supplying Oxygen 93 Percent against it typically needs to show the procedure it follows to produce, test and release a batch, the calibration record for its analysis equipment, the quality certificate tied to the pharmacopoeia a contract calls for, and the training record for the pharmacists and medical technicians who carry out the work.
ComplyTrain gives a supplier a controlled place to hold that kind of evidence: the documented procedure, the record tying a delivered batch's certificate to the national legislation and pharmacopoeia a contract specified, the calibration log, and the training record for the staff involved. It does not operate a MOGS or POGS, run the gas analysis, calibrate the equipment, or issue a quality certificate - that remains work done on the equipment itself, not in software.
Which pharmacopoeia and which national reservation actually apply to a given tender is set by the contract and the customer's own quality clause, not by this page; the standards explorer shows what else sits alongside AMedP-8.17 in the medical family, and we are glad to talk through what a specific requirement is asking for.
Questions
Is AMedP-8.17 mandatory?
It binds a nation only once that nation has agreed to use it, which the promulgation record ties to STANAG 2558; nations can and do ratify with reservations, and four have against this edition. For a supplier, it becomes a requirement only where a contract or tender for oxygen generating systems, containers or field-produced medicinal oxygen specifies it or a customer's own implementation of it.
Can a company be certified to AMedP-8.17?
No. The document names no certification scheme, no accredited body and no inspection regime. Conformity is shown through a quality certificate accompanying each batch and the sampling, analysis and calibration records the document describes, held against whichever national pharmacopoeia applies, not through a certificate issued against AMedP-8.17 itself.
What is the difference between AMedP-8.17 and STANAG 2558?
STANAG 2558 is the agreement by which nations commit to use AMedP-8.17; AMedP-8.17 is the Allied Medical Publication that actually sets the minimum requirements for producing and testing Oxygen 93 Percent.
Does AMedP-8.17 replace national pharmacopoeia requirements for oxygen?
No. It requires the oxygen produced to meet the United States Pharmacopoeia - National Formulary or European Pharmacopoeia monographs, depending on the national legislation of the manufacturing nation, and adds requirements specific to producing it on operations rather than replacing the underlying pharmacopoeia.
What edition is current, and what did it replace?
Edition A, Version 2, promulgated in December 2021, is the current edition. It took effect on receipt and superseded Edition A, Version 1 of AMedP-8.17.